EUVIMEDEUVIMED entdecken
Übersichtsarbeit

A Review of Labeling Based on Patient-Reported Outcome Endpoints for New Oncology Drugs Approved by the European Medicines Agency (2017-2021)

Ari Gnanasakthy, Courtney Levy, Lindsey Norcross, Lynda Doward, Randall Winnette

Value in Health · 2023

DOI: 10.1016/j.jval.2023.01.017 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Value in Health, 2023. Verfasst von Ari Gnanasakthy und 4 weiteren Autor:innen. Beteiligte Einrichtung: RTI Health Solutions, Research Triangle Park, NC, USA. Electronic address: gnanasakthy@rti.org. Hauptthemen laut MEDLINE: Quality of Life, Neoplasms. Die Arbeit wurde bisher 19-mal zitiert (Crossref) und nennt 24 Literaturangaben. Gefördert von: Pfizer.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

OBJECTIVE: A review of new oncology indications approved by the European Medicines Agency (EMA) for 2012-2016 showed that 33% of new drugs had labeling based on patient-reported outcomes (PROs). We reviewed labeling text based on PRO endpoints for new oncology indications approved during 2017-2021. METHODS: New oncology drugs approved by EMA to treat indications of cancers during 2017-2021 were identified from the EMA website. PRO-related language reported in EMA summaries of product characteristics (SmPCs) were summarized and compared with similar findings reported for oncology indications approved during 2012-2016. RESULTS: Review documents by the EMA during 2017-2021 were available for 49 new oncology drugs for 70 cancer indications. Submissions for 52 (74.3%) of the 70 indications included PRO data for EMA review. Of all submissions, 14 (20.0%) approvals contained PRO-related language in the SmPC. Broad concepts such as health-related quality of life were most common and found in 8 of 14 (57.1%) PRO-related labels. CONCLUSION: PRO-related language appeared in SmPCs for 20% of all indications of new oncology drugs approved by EMA during 2017-2021 compared with approximately 33% of EMA approvals during 2012-2016. PRO-related labeling during the same periods showed a greater decline (from 47% to 27%) for indications of new oncology drugs that also included PRO data. One possible reason for this decline may be the increase in open-label studies from 62% between 2012 and 2016 to approximately 79% between 2017 and 2021.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Quality of LifeNeoplasmsHumansMedical OncologyPatient Reported Outcome MeasuresDrug ApprovalEurope

Stichwörter der Autor:innen

labelingpatient-reported outcomesregulatory review (European Medicines Agency)review

Autor:innen und Institutionen

  • RTI Health Solutions, Research Triangle Park, NC, USA. Electronic address: gnanasakthy@rti.org.
  • RTI Health Solutions, Manchester, England, UK.
  • RTI Health Solutions, Research Triangle Park, NC, USA.
  • Pfizer Inc, New York City, NY, USA.

Förderung

  • Pfizer

Zitieren

APA

Gnanasakthy, A., Levy, C., Norcross, L., Doward, L., & Winnette, R. (2023). A Review of Labeling Based on Patient-Reported Outcome Endpoints for New Oncology Drugs Approved by the European Medicines Agency (2017-2021). Value in Health. https://doi.org/10.1016/j.jval.2023.01.017

Vancouver

Gnanasakthy A, Levy C, Norcross L, Doward L, Winnette R. A Review of Labeling Based on Patient-Reported Outcome Endpoints for New Oncology Drugs Approved by the European Medicines Agency (2017-2021). Value in Health. 2023. doi:10.1016/j.jval.2023.01.017

BibTeX
@article{Gnanasakthy2023,
  author = {Gnanasakthy, Ari and Levy, Courtney and Norcross, Lindsey and Doward, Lynda and Winnette, Randall},
  title = {A Review of Labeling Based on Patient-Reported Outcome Endpoints for New Oncology Drugs Approved by the European Medicines Agency (2017-2021)},
  journal = {Value in Health},
  year = {2023},
  doi = {10.1016/j.jval.2023.01.017}
}
Kostenlos starten →